



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009

## CytRx

[View the current CytRx Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/3194-CytRx.html>)

### Contact Details:

**11726 San Vicente Blvd Suite 650**

**Los Angeles**

**California**

**90049**

**United States of America**

Tel: (310) 826-5648

Fax: (310) 826-6139

Email: [mwachs@ceocast.com](mailto:mwachs@ceocast.com)

CytRx Corporation (NASDAQ: CYTR), located in Los Angeles, California, is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines. CytRx's small molecule drug candidates provide cellular protection by activating "molecular chaperone" proteins that can repair or degrade proteins that are believed to cause many diseases. "Molecular chaperones" represent a therapeutic development platform from which CytRx may derive several drugs that address large markets and unmet medical needs. CytRx initiated a Phase II clinical trial with arimoclomol in ALS in September 2005. The initial Phase II trial included 84 patients treated at 10 clinical sites in the United States with initial results expected in 4Q '06. The FDA has granted Fast Track and Orphan Drug designation for arimoclomol in ALS. CytRx is a world leader in developing products based on advanced RNAi technology primarily for the human health care market. RNAi has been shown to effectively silence a targeted disease-causing gene within a living cell. CytRx has a broad based strategic alliance with the University of Massachusetts Medical School (UMMS) which has given the company unparalleled access to RNAi technology and serves as a broad platform for a myriad of drug discovery applications including obesity, type 2 diabetes, ALS (Lou Gehrig's disease), and CMV (cytomegalovirus). Additionally, CytRx has a sponsored research program with Massachusetts General Hospital, Harvard's teaching hospital, to develop therapies to treat ALS using RNAi. CytRx has also licensed from the UMMS the exclusive worldwide commercial rights to a novel DNA-based HIV vaccine technology. The HIV vaccine is based on a unique cocktail of human HIV-1 primary isolates from several genetic subtypes of HIV. Phase I clinical results announced in July 2006 indicate that the DNA + protein boost HIV vaccine, based on 5 known primary human HIV strains, was well tolerated and produced potent antibody responses with neutralizing activity against multiple HIV viral strains. This clinical program, was funded by a \$16 million NIAID grant, was being conducted by CytRx, University of Massachusetts Medical School (UMMS) and Advanced BioScience Laboratories (ABL).

- [Identification of small-molecule HSF1 amplifiers by high content screening in protection of cells from stress induced injury.](#)  
*Small molecule amplifiers of heat shock response have shown promising...* 27th October, 2009  
Department of Biology, CytRx Corporation, 3030 Bunker Hill Street, Suite- Biochem Biophys Res Commun. 2009 Oct 21. ([DOI Direct Link](#))
- [Pyrimido\[5,4-e\]\[1,2,4\]triazine-5,7\(1H,6H\)-dione derivatives: their cytoprotection effect from rotenone toxicity and preliminary DMPK properties.](#)  
*Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives exhibited...* 30th September, 2009  
CytRx Corporation, 3030 Bunker Hill Street, Suite 101, San Diego, CA- Bioorg Med Chem Lett. 2009 Nov 1;19(21):6114-8. Epub 2009 Sep 10. ([DOI Direct Link](#))
- [Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity.](#)  
*As a member of the class III histone deacetylases, Sirtuin-2 (SIRT2) is...* 12th August, 2009  
Department of Biology, CytRx Corporation, 3030 Bunker Hill Street, Suite- Biochem Biophys Res Commun. 2009 Sep 4;386(4):729-33. Epub 2009 Jun 25. ([DOI Direct Link](#))
- [Chloro-oxime derivatives as novel small molecule chaperone amplifiers.](#)  
*Chloro-oxime derivatives were investigated as novel small molecule...* 18th July, 2009  
CytRx Corporation, - Bioorg Med Chem Lett. 2009 Jun 1;19(11):3128-35. Epub 2009 Mar 9. ([DOI Direct Link](#))
- [Pyrimido\[5,4-e\]\[1,2,4\]triazine-5,7\(1H,6H\)-dione derivatives as novel small molecule chaperone amplifiers.](#)  
*Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives were...* 9th June, 2009  
Department of Chemistry, CytRx Corporation, 3030 Bunker Hill Street, Suite- Bioorg Med Chem Lett. 2009 Aug 1;19(15):4303-7. Epub 2009 May 27. ([DOI Direct Link](#))
- [Identification of Chaulmoogric Acid as a Small Molecule Activator of Protein Phosphatase 5.](#)  
*Protein phosphatase 5 (PP5) is an important protein phosphatase that is...* 1st May, 2009  
Department of Biology, CytRx Corporation, 3030 Bunker Hill Street, Suite- Appl Biochem Biotechnol. 2009 Apr 30. ([DOI Direct Link](#))
- [High-content image-based screening for small-molecule chaperone amplifiers in heat shock.](#)  
*Heat shock proteins represent the major elements of the cellular stress...* 11th April, 2009  
Department of Biology, Cytrx Corporation, San Diego, CA 92109, USA.- J Biomol Screen. 2008 Dec;13(10):953-9. Epub 2008 Nov 17. ([DOI Direct Link](#))
- [Crystal structure of HsEg5 in complex with clinical candidate CK0238273 provides insight into inhibitory mechanism, potency, and specificity.](#)  
*HsEg5 is an important mitotic kinesin responsible for bipolar spindle...* 25th July, 2008  
ArQule Biomedical Institute, ArQule Incorporated, 333 Providence Highway, - Biochem Biophys Res Commun. 2008 Aug 8;372(4):565-70. Epub 2008 May 27. ([DOI Direct Link](#))
- [Microwave-assisted, boron trichloride mediated acylation of phenols-synthesis of \(o-hydroxyaryl\)\(aryl\)methanones and xanthenes.](#)  
*A novel and efficient microwave-assisted, BCl(3) mediated coupling...* 17th August, 2006  
CytRx laboratories, Inc., Worcester, Massachusetts 01605, USA.- J Comb Chem. 2006 May-Jun;8(3):361-7. ([DOI Direct Link](#))
- [In silico design and synthesis of piperazine-1-pyrrolidine-2,5-dione scaffold-based novel malic enzyme inhibitors.](#)  
*Fragment-based virtual library design and virtual screening have been...* 29th March, 2006  
Cytrx Laboratories, One Innovation Drive, Worcester, MA 01605, USA.- Bioorg Med Chem Lett. 2006 Feb;16(3):525-8. Epub 2005 Nov 8. ([DOI Direct Link](#))

- [Kinase inhibitor recognition by use of a multivariable QSAR model.](#)  
We have applied a retrosynthetic program to determine the scaffold and...18th March, 2006  
CytRx Laboratories, 1 Innovation Drive, Worcester MA 01605, USA.- J Mol Graph Model. 2006  
Jan;24(4):278-95. Epub 2005 Oct 25. ([DOI Direct Link](#))
- [Microwave-assisted synthesis of salicylamide via BCl3 mediated coupling.](#)  
A novel and efficient microwave-assisted, BCl3-mediated coupling reaction...24th February, 2006  
CytRx Laboratories, Inc., One Innovation Drive, Worcester, Massachusetts- J Comb Chem. 2005  
Jul-Aug;7(4):622-6. ([DOI Direct Link](#))
- [Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans.](#)  
Purified poloxamer 188 (PP188) is a nonionic, block copolymer surfactant...28th March, 2003  
CytRx Corporation, 154 Technology Parkway, Suite 200, Norcross, Georgia- J Pharm Sci. 2002  
Sep;91(9):1936-47. ([DOI Direct Link](#))
- [Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man.](#)  
Purified poloxamer 188 (PP188) is a non-ionic, block copolymer surfactant...3rd December, 2002  
Drug Development, CytRx Corporation, Norcross, GA 30092, USA.- Biopharm Drug Dispos. 2002  
Apr;23(3):87-103. ([DOI Direct Link](#))

### Press Releases on CytRx:

<a href="#">Reportlinker Adds World Neurodegenerative Diseases Market 2009-2024</a>	3rd November, 2009	Reportlinker	-- Rilutek. In our pipeline analyses we include emerging therapeutics such as stem cells, gene therapy and monoclonal antibodies, among other prominent developments. Detailed analysis of the
<a href="#">New Report Just Published: World Multiple Myeloma Therapeutics Market Report</a>	7th July, 2009	Reportlinker	NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Multiple Myeloma Therapeutics Market <a href="http://www.reportlinker.com/p0119496/World">http://www.reportlinker.com/p0119496/World</a>
<a href="#">New Report from PharmaPlus: HIV Pipelines &amp; Deals</a>	1st December, 2003	Pharmaplus	New Report from PharmaPlus: HIV Pipelines & Deals At the end of November 2003 the joint United Nations Program on HIV/AIDS and the World Health Organization presented

### BioNews Results for CytRx



- [CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer](#)  
Business Wire UK: Nov 18 2009 1:37PM Matching: cytrx
- [CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer](#)  
Business Wire via Yahoo!: Nov 18 2009 2:22PM Matching: cytrx
- [CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer](#)  
News-Medical.Net: Nov 18 2009 8:58PM Matching: cytrx
- [CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer](#)  
Genetic Engineering News: Nov 18 2009 2:55PM Matching: cytrx

- [CytRx to initiate Phase II gastric cancer trial](#)  
*Individual.com: Nov 21 2009 6:26AM Matching: cytrx*
- [BiomedReports: News and FDA Updates for Clinical Data \(NASDAQ:CLDA\), Delcath \(Nasdaq:DCTH\), CytRx \(NASDAQ:CYTR\)](#)  
*Individual.com: Nov 20 2009 8:41AM Matching: cytrx*
- [CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer](#)  
*Pharma Live: Nov 19 2009 2:11AM Matching: cytrx*
- [CytRx To Initiate Phase 2 Clinical Trial With INNO-206 In Patients With Advanced Gastric Cancer](#)  
*Medical News Today: Nov 19 2009 7:51PM Matching: cytrx*
- [Medical News: CytRx To Initiate Phase 2 Clinical Trial With INNO-206 In Patients With Advanced Gastric Cancer](#)  
*BioFind: Nov 19 2009 5:49PM Matching: cytrx*
- [News and FDA Updates for Clinical Data \(NASDAQ:CLDA\), Delcath \(Nasdaq:DCTH\), CytRx \(NASDAQ:CYTR\)](#)  
*Los Angeles Chronicle: Nov 19 2009 9:16PM Matching: cytrx*
- [Focusing on Key Indications, Securing Partnerships Top Goals for New RXi CEO](#)  
*GenomeWeb: Nov 18 2009 11:57PM Matching: cytrx*
- [CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer](#)  
*Reuters: Nov 18 2009 2:37PM Matching: cytrx*
- [CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer](#)  
*Street Insider: Nov 18 2009 2:01PM Matching: cytrx*
- [CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer](#)  
*Business Wire: Nov 18 2009 1:47PM Matching: cytrx*
- [CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer](#)  
*RBC Dain Rauscher: Nov 18 2009 1:42PM Matching: cytrx*

#### CytRx Clinical Trials:



- [Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL](#)

#### CytRx Patents:



- 7550457- [Pharmaceutically effective compounds](#)
- 5990241- [Polyoxypropylene/polyoxyethylene copolymers with improved biological activity](#)
- 5824322- [Compositions and methods for growth promotion](#)
- 5696298- [Polyoxypropylene/polyoxyethylene copolymers with improved biological activity](#)

- 5691387- [Polyoxypropylene/polyoxyethylene copolymers with improved biological activity](#)
- 5674911- [Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use](#)
- 5567859- [Polyoxypropylene/polyoxyethylene copolymers with improved biological activity](#)
- 5523492- [Polyoxypropylene/polyoxyethylene copolymers with improved biological activity](#)
- 5494660- [Method for inhibiting microbial binding to surfaces](#)
- 6086899- [Vaccine adjuvant and vaccine](#)
- 6149922- [Vaccine adjuvant and vaccine](#)
- 7384936- [Carboxamide derivatives and their use in the treatment of vascular diseases](#)
- 7361655- [Pharmaceutically effective compounds](#)
- 7148239- [Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof](#)
- 7126002- [Pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds](#)
- 7045576- [Adjuvants and copolymer compositions](#)
- 6747064- [Polyoxypropylene/polyoxyethylene copolymers with improved biological activity](#)
- 6416947- [Vaccine adjuvant and vaccine method](#)
- 6359014- [Polyoxypropylene/polyoxyethylene copolymers with improved biological activity](#)
- 5407445- [Gel composition for implant prosthesis and method of use](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.  
UK Tel: (+44) 1300 321501  
USA Voicemail and Fax: (+1) 415 680 2472  
[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,  
Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10  
Copyright 1997-2009 - BioPortfolio Limited.

